BALTIMORE ( Stockpickr) -- It may seem surprising, but investors hate pharmaceutical stocks right now. Or maybe it's more surprising that harnessing that hate could be a very good thing for buyers this summer.By and large, investors have been hating on pharmaceutical stocks for the last few years. And they've got their reasons: health care reform drama on Capitol Hill, the treacherous cliff of patent expirations, and a market that's already pretty anxiety-ridden haven't helped. That's a big part of the reason why drugmakers boast such big dividend yields right now; they're being discounted for perceived risk.
Buy the 5 Pharma Stocks Everyone Hates
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts